Basic self-disturbance trajectories in clinical high risk for psychosis: a one-year follow-up study

Tor Gunnar Værnes1,2 · Jan Ivar Røssberg3,4 · Ingrid Melle4 · Barnaby Nelson5,6 · Kristin Lie Romm1,7 · Paul Møller8

Received: 20 February 2021 / Accepted: 19 October 2021 / Published online: 16 November 2021
© The Author(s) 2021

Abstract
Basic self-disturbance (BSD) has been proposed as a driver of symptom development in schizophrenia spectrum disorders (SSDs). In a one-year follow-up of 32 patients (15–30 years) at putative risk for psychosis, we investigated trajectories of BSD levels from baseline to follow-up, and associations between clinical characteristics at baseline and follow-up, including follow-up levels of BSD (assessed with the EASE). Clinical high risk (CHR) for psychosis status and symptom severity were assessed with the SIPS/SOPS scales and also according to the cognitive basic symptoms high-risk criteria (COGDIS). DSM-IV diagnoses, functioning and other clinical characteristics were assessed with standard clinical instruments. Higher severity of negative symptoms and meeting COGDIS criteria at baseline were associated with higher BSD levels at follow-up. All measured at follow-up, higher BSD levels correlated with higher severity of positive, negative, disorganization and general symptoms, and with a lower level of global functioning. We found higher BSD levels at follow-up in subjects with schizotypal personality disorder (SPD) at baseline (n = 5) and in SSDs at follow-up (n = 12, including nine with SPD). Mean BSD levels decreased significantly from baseline to follow-up, but individual trajectories varied considerably. Increased BSD levels were associated with higher baseline BSD levels, non-remission of positive symptoms and functional decline. Overall, the current study indicates that subgroups in the CHR population with a higher risk of non-remission or deterioration may be identified by supplementing CHR criteria with assessment of BSD and negative symptoms.

Keywords Basic self-disturbance · Anomalous self-experience · Clinical high-risk for psychosis · Schizophrenia spectrum · Functioning · Negative symptoms

Introduction
In a phenomenological model of schizophrenia, first developed by Sass and Parnas, a core feature of this disorder is considered a self-disorder, also termed an ‘ipseity disturbance’ or a ‘basic self-disturbance’ (BSD). The model describes an instability in the basic sense of self, characterized by ‘diminished self-presence’, i.e. disturbances in subjectivity and implicit “ownership” of experience and action, ‘hyperreflexivity’, i.e. an exaggerated self-consciousness involving self-alienation, and ‘disturbed grip or hold’, involving loss of salience, stability and significance.
of objects in the field of awareness [35, 36, 62, 65, 67]. BSD is assumed to drive symptom development and articulation over the course of the schizophrenia prodrome, and to underlie and connect the seemingly disparate symptoms of all the schizophrenia spectrum disorders (SSDs) [17, 22, 42, 56, 58, 62, 65, 67, 74].

A range of studies have consecutively demonstrated that SSDs and the schizophrenia prodrome are characterized by a panoply of anomalies of self-experience, assumed to reflect BSD [8, 34, 39, 40, 44, 45, 47, 50, 56–58]. These anomalies have been shown to aggregate in SSDs compared to other diagnostic groups and healthy controls, as described in a recent meta-analysis (e.g. SSD vs. bipolar or affective disorders, Hedges $g = 1.8$, CI = 1.4 to 2.2, and SSD vs healthy controls, Hedges $g = 1.8$, CI = 1.5 to 2.0 [57].

To detect, and hopefully prevent, development of psychotic disorders, clinical high-risk (CHR) criteria for psychosis are extensively used in research and clinical settings [21, 69, 72]. The CHR concept is currently based on two different sets of criteria: (1) the ultra-high risk (UHR) criteria, and (2) the basic symptoms high-risk criteria [19, 72]. Several studies have demonstrated that BSD phenomena are common in CHR samples [13, 14, 37, 54, 77], although less frequent than in SSDs [57]. However, prospective studies of BSD in CHR samples are sparse. One study found that a higher level of BSD was associated with transition to psychosis in an UHR sample. Being diagnosed with SSDs (including both psychotic SSDs and schizotypal or schizoid personality disorder) was also associated with higher BSD levels [37]. In a previous communication from the current research project, we found that non-remission of attenuated psychotic symptoms and functional deficits was associated with higher baseline levels of BSD [80]. It could also be noted that in a seven-year follow-up study of non-psychotic help-seeking adolescents (i.e. not restricted to CHR), future SSD diagnoses were significantly predicted by BSD levels [24].

To our knowledge, no studies have prospectively investigated the persistence of BSD phenomena in CHR, and how BSD trajectories and BSD levels at follow-up may be related to symptoms, other clinical characteristics and functioning at baseline and follow-up. This is of importance because it may help us identify CHR subjects at the highest risk of adverse clinical and functional outcomes, and to derive a more nuanced picture of the stability of BSD in CHR.

In this exploratory study, our aims were to address the following questions in a one-year follow-up of a CHR sample:

1) To what extent are clinical characteristics and functioning at baseline associated with the severity of BSD at one-year follow-up?
2) To what extent is the severity of BSD at one-year follow-up associated with clinical characteristics and functioning at follow-up?
3) How stable is BSD from baseline to one-year follow-up?
4) Are different BSD trajectories associated with differences in clinical and functional characteristics at baseline, and with changes in these characteristics from baseline to follow-up?

### Methods

#### Setting and participants

The present study was a one-year follow-up of patients from child/adolescent and adult outpatient units in Oslo and adjacent catchment areas (Oslo University Hospital, Diakonhjemmet Hospital, Vestre Viken Hospital Trust and Akerhus University Hospital). Patients were referred to the study if they were clinically suspected by their treating clinicians to be at increased risk of psychosis, and were consecutively recruited and assessed at baseline from June 2012 to December 2015. All participants gave written informed consent. For those below 18 years, parents consented as well. The study was part of the Norwegian Thematically Organized Psychosis (TOP) study, and was approved by the Regional Committee for Medical Research Ethics in Norway (permission number 2011/1070 D).

Inclusion criteria were age between 15 and 30 years, and meeting CHR criteria for one or more of the following UHR syndromes: the Attenuated Positive Symptom Syndrome (APSS), the Brief Intermittent Psychotic Symptoms (BIPS) syndrome or the Genetic Risk and Deterioration (GRD) syndrome, as outlined in the Structured Interview for Prodromal Syndromes (SIPS) [29] (see Table 1). An APSS syndrome in this SIPS version does not require social/occupational dysfunction, as in the CAARMS attenuated psychosis group [20], or distress/disability, as in the DSM-5 APS syndrome [1, 61].

In addition, we did not exclude patients with longstanding, non-progressive attenuated psychotic symptoms. They met criteria for an APSS syndrome [29], except the recent onset/progression criteria. We termed these subjects the ‘non-progressive symptoms group’. They would possibly have met the criteria for an APSS syndrome with the ‘current status specifier’ ‘persistence’ in the current version of the SIPS (version 5.6) [81]. Subjects with persistent risk symptoms may be at risk of a range of adverse clinical and functional outcomes, although the risk for conversion to psychosis is lower than in CHR subjects with progressive symptoms [3, 18, 68, 81]. All subjects were also assessed with respect to cognitive basic symptoms high-risk criteria.
We excluded subjects who met one or more of the following criteria: current or past psychotic disorder (DSM-IV Axis 1 criteria), being treated with antipsychotics currently or for ≥ 4 weeks lifetime (dose equivalent to ≥ 5 mg Olanzapine per day), clearly drug-induced CHR symptoms, neurological disorders or severe medical conditions, intellectual disability (IQ < 70), and incapacity to speak/comprehend Norwegian.

The original baseline sample comprised 38 participants, including seven in the non-progressive symptoms group. Six subjects (5 CHR, 1 non-progressive) did not take part in the assessments at follow-up, i.e. a drop-out rate of 15.8%. Hence, 32 subjects took part in the current follow-up study, including six in the non-progressive symptoms group. There were no significant differences in baseline demographic or clinical characteristics between these 32 and the six drop-outs (supplementary material S1. The original baseline sample is also described in a previous study [77]).

Measures and procedure

Baseline assessments

Baseline assessments included socio-demographic data and the Structured Interview for Prodromal Syndromes/Scale of Prodromal Symptoms (SIPS/SOPS) [29, 30], Norwegian version 5.0, Jan 2012. The SIPS/SOPS was used for assessing UHR criteria and non-progressive symptoms criteria, and the last month severity of positive, negative, disorganization and general symptoms (ranging each symptom on the SOPS from 0 = absent to 6 = psychotic/extreme) [31]. Inter-rater reliability regarding

Table 1 UHR/COPSa, non-progressive symptoms criteria, and COGDISb criteria

| Prodromal syndromes                  | Criteria of Prodromal Syndromes (COPS)                                                                 |
|--------------------------------------|--------------------------------------------------------------------------------------------------------|
| Attenuated Positive Symptom syndrome (APSS)       | One or more of the 5 SOPS positive items scoring in the prodromal range (rating of 3–5)                  |
| Scale of Prodromal Symptoms (SOPS), positive sub-scale, include: unusual thought content/delusional ideas, suspiciousness/persecutory ideas, grandiosity, perceptual abnormalities/hallucinations and disorganized communication | AND                                                                                           |
|                                      | Symptoms beginning within the past year or currently rate at least one scale point higher than it would if rated 12 months ago |
|                                      | Symptoms occurring at least once per week for last month                                                 |
| Brief Intermittent Psychotic Symptom (BIPS) syndrome | One or more of the 5 SOPS positive items in the psychotic range (rating of 6) that do not meet Presence of Psychotic Syndrome (POPS) criteria in the SIPS |
|                                      | Symptoms beginning in the past 3 months                                                                    |
|                                      | Symptoms occurring currently at least several minutes per day at least once per month                   |
| Genetic Risk and Deterioration (GRD) syndrome    | First degree relative with history of any psychotic disorder                                             |
|                                      | OR                                                                                                       |
|                                      | Criteria for schizotypal personality disorder met in patient                                              |
|                                      | AND                                                                                                       |
|                                      | GAF drop of at least 30% over the last month vs 1 year ago                                                 |
| Non-progressive symptoms group         | Criteria for the non-progressive symptoms group                                                           |
|                                      | One or more of the 5 SOPS positive items scoring in the prodromal range (rating of 3–5)                  |
|                                      | AND                                                                                                       |
|                                      | Symptoms occurring at least once per week for last month                                                 |
| COGDIS items                          | COGDIS criteria                                                                                         |
| Inability to divide attention, thought interference, thought pressure, thought blockages, disturbance of receptive speech, disturbance of expressive speech, unstable ideas of reference, disturbances of abstract thinking, captivation of attention by details of the visual field | Presence of ≥ 2 of the 9 basic symptoms with a SPI-A score of ≥ 3 within the last 3 months |

a Descriptions are from the SIPS [30], Norwegian version 5.0 (Jan. 2012)

b The listed COGDIS items and criteria are obtained from: Schultze-Lutter F, Addington J, Ruhrmann S, Klosterkötter J [70] Schizophrenia Proneness Instrument – Adult version (SPI-A). Giovanni Fiori Editore, Roma
SOPS scores and prodromal/psychosis-risk syndrome diagnostic agreement have been found to be excellent in early studies and in a more recent review [29, 30, 82]. Studies are sparse, but also find the predictive and construct validity of the SIPS/SOPS to be satisfactory [82]. The non-progressive symptoms criteria were not tested for validity and reliability. Considering the overlap with criteria for the CHR “persistence” syndrome, it could be noted that this new CHR classification system has shown promising validity [81].

BSD phenomena were assessed with the Examination of Anomalous Self-Experiences (EASE) (lifetime experiences). The EASE comprises 57 main items organized in five domains: (1) Cognition and stream of consciousness, (2) Self-Awareness and presence, (3) Bodily experiences, (4) Demarcation/Transitivism, and (5) Existential reorientation (supplementary material S2) [49]. All EASE items were scored on a 0–4 severity Likert scale, but following other similar studies [24, 39, 54] we subsequently converted these scores into dichotomous 0–1 scores, indicating that the symptom had been absent or questionably present (0), or definitively present (1). The EASE has been found to have good to excellent internal consistency and inter-rater reliability [33, 37, 41, 55].

SIPS and EASE interviews were videotaped at baseline and follow-up. Based on retrospective inspection of the baseline EASE interviews, we did an additional baseline scoring of all the EASE items (0–1 scores), reflecting present or last year experiences. COGDIS criteria were assessed according to descriptions in the Schizophrenia Proneness Instrument – Adult version (SPI-A) [70], using all available information including the EASE and SIPS interviews. There is a considerable overlap between the descriptions of the COGDIS symptoms in the SPI-A and certain EASE items [49, 70]. The SPI-A has demonstrated good inter-rater reliability [71], and the predictive validity of the COGDIS criteria is comparable to the UHR criteria [60, 72].

Clinical DSM-IV Axis I diagnoses were allocated after an assessment with a full version of the SCID-I [16]. A checklist included in the SIPS for the DSM-IV criteria for Schizotypal Personality Disorder (SPD) was used for assessment of this disorder. We categorized SPD as schizophrenia spectrum disorder, in line with DSM-5 and the understanding of SPD among experts in the field [1, 15, 48, 73]. Present (last week) global functioning was assessed with a split version of the Global Assessment of Functioning scale (S-GAF). S-GAF is divided into a symptom score and a functioning score, ranging in severity from 0 (extreme dysfunction) to 100 (superior function) [51]. Only the functioning scores (GAF-F) are reported here. Childhood (0–11 years) and early adolescent (12–15 years) functioning were assessed with the Premorbid Adjustment Scale (PAS) [9], and adverse childhood experiences with the self-report inventory Childhood Trauma Questionnaire – short form (CTQ-SF) [6]. CTQ-SF include 28 items and categorize experiences in five domains: physical abuse, sexual abuse, emotional abuse, emotional neglect and physical neglect [5].

Follow-up assessments

At follow-up, we did a reassessment with the SIPS/SOPS (based on last month), the EASE (covering last year, since baseline) and GAF-F (based on last week). In line with a recent recommendation from clinical and research experts in the field [52], we used a combined symptomatic and functional measure of remission. This was defined as a score of ≤ 2 on all SOPS positive symptom items, in combination with a score of ≥ 70 points or ≥ 10 points improvement on GAF-F (corresponding, but not identical, to the measure suggested by Polari et al. [52]). In the case of transition to psychosis between baseline and follow-up (reported from treating clinicians), this was evaluated according to the criteria for a psychotic syndrome in the SIPS [29, 30], followed by a differential diagnostic assessment with the SCID-I, module 1, A-E chapters [16]. Non-transitioning subjects were not reassessed with the SCID-I, but all participants were reassessed at follow-up with the SPD checklist in the SIPS.

Clinical interviews at baseline and follow-up were performed by TGV. He had participated in the TOP study SCID-I reliability and training program, and had been trained in the use of the SIPS and EASE by Norwegian experts in the field, including supervision in the use of EASE by PM, one of the authors and certified instructors of the EASE. Inter-rater reliability was tested on the SIPS and EASE, revealing excellent reliability for the SIPS and moderate reliability for the EASE (for details, see [77]). DSM-IV diagnoses, CHR status and EASE scores were regularly discussed with PM and JIR, both experienced researchers and psychiatrists.

Statistical analysis

All statistical analyses were performed with SPSS version 25.0. Non-parametric tests were used, and if not otherwise specified, the significance threshold was set at 0.05. The severity level of BSD was determined by summing up the dichotomous 0–1 scores on all the 57 main EASE items, giving an EASE total score. Likewise, the severity level of positive, negative, disorganization and general symptoms was determined by summing up the scores on the SOPS subscales. All tests of normality of the distribution of scores were conducted with the Kolmogorov–Smirnov statistic, and we inspected skewness and kurtosis values. Group
comparisons of categorical variables were conducted with chi-square statistics.

The EASE total scores at follow-up were positively skewed, clustering at the low values. Correlations between EASE total at follow-up and continuous variables at baseline (first research question) and follow-up (second research question) were tested with Spearman’s rho (two-tailed). These analyses were Bonferroni-adjusted for multiple comparisons (alpha level \( p < 0.006 \) (0.05/9 variables) in the first analysis, and \( p < 0.01 \) (0.05/5 variables) in the second analysis. In the first analysis, we included the CTQ subscale Emotional neglect, but not the other CTQ subscales, given a stronger association \( (p < 0.05) \) with EASE total at baseline [77]. Analyses of whether differences in EASE total at follow-up were associated with categorical variables at baseline or follow-up were conducted with the Mann–Whitney U Test.

To answer the third and fourth research question, we used the Wilcoxon signed rank test to analyze differences in EASE total between baseline and follow-up. Baseline EASE total scores based on current/last year experiences were included in these analysis (thus comparing the presence of anomalous self-experiences from one year to the next year). One outlier with the strongest increase in EASE scores was included in the analyses, as the inclusion of this outlier did not significantly affect the results.

By inspection of the individual EASE trajectories, we did an ad hoc categorization into three groups: 1) subjects with an increase \( (\geq 1 \text{ points}) \) in EASE total, 2) subjects with 0–3 points decline in EASE total and 3) subjects with >3 points decline in EASE total. We chose this approach over statistical clustering approaches due to the small sample size. Four SOPS subscale change variables and a GAF-F change variable were computed (follow-up minus baseline scores). Differences between the three groups in the scores on the baseline variables and the scores on the SOPS change and GAF-F change variables were analyzed with the Kruskal–Wallis test.

**Results**

Demographics and clinical characteristics at baseline and one-year follow-up

Twenty-six participants were meeting formal CHR criteria, and six were assessed as ‘non-progressive’, at baseline. A majority \( (n = 24, 92\%) \) met criteria for an APSS syndrome, either alone or in combination with COGDIS criteria or a GRD syndrome (only one). In Table 2, demographic and clinical characteristics of the sample \( (n = 32) \) are shown. The six participants in the non-progressive symptoms group did not differ significantly from the CHR group in clinical or demographic characteristics, except for being approximately five years older and having approximately one more year of education (supplementary material S3). Medication at baseline had no association to clinical variables at baseline.

The mean follow-up time was 13 months \( (\text{Sd} = 1.7) \). The participants received treatment as usual at their local health services between baseline and follow-up, including standard medication, psychotherapy and psychosocial interventions (e.g. family support and work/school adjustments). Outcomes at follow-up were not significantly affected by these treatment variables, or by hospitalizations or discontinuation of treatment. Investigations of relationships between demographic characteristics and clinical and functional outcomes at baseline or follow-up did not reveal any significant associations.

Among the four participants who transitioned to psychosis, three were assigned a DSM-IV SSD diagnosis (2 schizophrenia, 1 schizophreniform disorder). The fourth was diagnosed with DSM-IV Psychosis NOS. Nine were diagnosed with SPD at follow-up (increased from five at baseline). We categorized these nine as schizophrenia spectrum subjects, along with the three with schizophrenia and schizophreniform disorder \( (n = 12, \text{i.e. 37.5\% of the sample}) \).

**Clinical characteristics at baseline were associated with EASE total at follow-up**

Correlations between baseline variables and EASE total at follow-up are shown in Table 3. The scores on the SOPS negative, SOPS disorganization and PAS Early Adolescence subscales correlated with EASE total at a significance level of \( p < 0.05 \), but after Bonferroni-correction \( (p < 0.006) \), only the association with SOPS negative was statistically significant, with a large effect size \( (r = 0.58) \).

Subjects meeting COGDIS criteria \( (n = 12) \) had significantly higher follow-up EASE total scores \( (\text{Md} = 18) \) than the other participants \( (n = 20, \text{Md} = 4.5) \), \( U = 59.5, p = 0.02 \), with a medium effect size \( (r = 0.42) \). This difference remained significant when EASE items clearly overlapping with COGDIS items (EASE items 1.1, 1.3, 1.4, 1.12, 1.17 and 5.1) were removed from the EASE total score, \( U = 64, p = 0.03 \). Baseline SPD subjects also had significantly higher EASE total scores at follow-up \( (n = 5, \text{Md} = 21) \) than the other subjects \( (n = 27, \text{Md} = 6) \), \( U = 28.5, p = 0.04, r = 0.36 \).

**Clinical characteristics and functioning at follow-up was associated with EASE total at follow-up**

All SOPS subscales and GAF-F at follow-up were significantly associated with EASE total at follow-up (Table 4), with large effect sizes \( (r > 0.60) \) for all these correlations. SSD subjects \( (n = 12, \text{at follow-up}) \) had significantly higher EASE total scores at follow-up \( (\text{Md} = 16.5) \) than

\[ \text{Human Language Model} \]
| Characteristics                                      | Baseline          | Follow-up         |
|------------------------------------------------------|-------------------|-------------------|
| Participants, n                                      | 32                | 32                |
| Male, n (%)                                          | 21 (65.6)         |                   |
| Age, mean (SD)                                       | 19.9 (3.8)        | 21.1 (4.0)        |
| Born in Norway, n (%)                               | 29 (90.6)         |                   |
| Employed or studying, n (%)                         | 17 (53.1)         |                   |
| Years of education, mean (SD)                       | 11.7 (1.8)        |                   |
| CHR positive, n (%), including:                      |                   |                   |
| APS only                                             | 14 (43.8)         | 2 (6.2)           |
| APS + COGDIS                                         | 9 (28.1)          | 1 (3.1)           |
| APS + GRD + COGDIS                                   | 1 (3.1)           | 1 (3.1)           |
| COGDIS only                                          | 2 (6.2)           | 5 (15.6)          |
| Non-progressive SOPS pos, n (%)                     | 6 (18.8)          | 4 (66.7)          |
| Transition to psychosis, n (%)                       | 4 (12.5)          |                   |
| Symptomatic and functional remission, n (%)\(^b\)   | 11 (34.4)         |                   |
| SOPS (number of items)                              |                   |                   |
| Positive (5), mean (SD)                             | 10.41 (3.45)      | 6.56 (5.58)       |
| Negative (6), mean (SD)                             | 12.50 (7.02)      | 9.94 (7.39)       |
| Disorganization (4), mean (SD)                       | 6.91 (3.36)       | 5.13 (4.32)       |
| General (4), mean (SD)                              | 7.59 (3.31)       | 4.97 (3.49)       |
| EASE total, mean (SD)/median                         |                   |                   |
| Baseline: lifetime                                   | 15.31 (8.01) / 13.50 |                   |
| Baseline: last year                                  | 13.78 (8.06) / 12.00 | 11.09 (10.03)/8.50 |
| GAF-F, mean (SD)                                     | 56.31 (10.83)     | 59.80 (15.72)     |
| Diagnoses                                            |                   |                   |
| Mood disorders, n (%)                                | 13 (40.6)         |                   |
| Anxiety disorders, n (%)                            | 8 (25.0)          |                   |
| Other Axis 1 disorders, n (%)                        | 4 (12.5)          |                   |
| Schizotypal pers. dis., n (%)                        | 5 (15.6)          | 9 (28.1)          |
| Schizophrenia, n (%)                                 | 2 (6.2)           |                   |
| Schizophreniform disorder, n (%)                    | 1 (3.1)           |                   |
| Psychosis NOS, n (%)                                 | 1 (3.1)           |                   |
| No DSM-IV diagnosis, n (%)                           | 2 (6.3)           |                   |
| Medication, prescribed\(^d\), n (%)                 |                   |                   |
| Antipsychotics                                       | 7 (21.9)          | 8\(^d\) (25.0)   |
| Antidepressants                                      | 6 (18.8)          | 10 (31.3)         |
| Anxiolytic                                           | 2 (6.3)           | 0                 |
| Anticonvulsants                                      | 1 (3.1)           | 1 (3.1)           |
| Psychostimulants                                     | 1 (3.1)           | 1 (3.1)           |
| Hospitalization between baseline and follow-up, n (%)| 3 (9.4)           |                   |
| Discontinuation of treatment before follow-up, n (%) | 8 (25)            |                   |

\(^a\) Meeting full CHR criteria, e.g. worsening of attenuated positive symptoms last year

\(^b\) ≤ 2 on all SOPS positive symptom items, in combination with a score of ≥ 70 points or ≥ 10 points improvement on GAF-F. Two of the 11 remitted subjects were from the non-progressive symptoms group

\(^c\) Data in the follow-up column represents prescribed medication between baseline and follow-up

\(^d\) 5 of the 8 had “Defined Daily Dose” below the recommended for antipsychotic treatment
subjects with no SSD \( (n = 20, \text{Md} = 4.5) \), \( U = 194.5, p = 0.003, r = 0.51 \) (highest in the three SSDs with psychotic disorders: \( \text{Md} = 28, \text{SPD subjects: Md} = 12) \). These SSD subjects also scored significantly higher on all the SOPS subscales at follow-up (SOPS positive and SOPS disorganization: \( p < 0.001, \text{SOPS negative: p} = 0.004 \), except for SOPS general \( p = 0.08 \), and at a significantly lower level of GAF-F \( p = 0.003 \). Among non-remitted subjects \( (n = 21) \), eleven were diagnosed with SSDs (9 of 11 with SPD) at follow-up. The non-remitted subjects \( (n = 21) \) had significantly higher EASE total scores at follow-up \( (\text{Md} = 14.5) \) than the fully remitted subjects \( (n = 11, \text{Md} = 1), U = 16.5, p < 0.001 \).

### EASE level trajectories, and their associations with clinical and other characteristics from baseline to follow-up

Individual trajectories of EASE scores from baseline to follow-up are illustrated in Fig. 1. Median EASE total in the full sample decreased from 12 at baseline to 8.5 at follow-up. This was a significant decline \( (z = -2.47, p = 0.01) \), with a moderate effect size \( (r = 0.31) \). There

![Individual trajectories in mean EASE total scores from baseline to follow-up](image)

**Table 3** Correlations between clinical and demographic characteristics at baseline and EASE total at one-year follow-up \( (n = 32) \)

| Baseline variables \( \rightarrow \) | SOPS Pos | SOPS Neg | SOPS Disorg | SOPS Gen | GAF-F | CTQ total | CTQ Emot. Negl | PAS Childhood | PAS Early adol |
|-----------------------------|---------|---------|-------------|----------|-------|-----------|----------------|--------------|---------------|
| EASE total at 1 year        | 0.17    | 0.58**  | 0.46*       | 0.20     | -0.30 | 0.11      | 0.26           | 0.22         | 0.38*         |

\(*p < 0.05, **p < 0.006\) (Bonferroni-adjusted), Spearman’s rho, two-tailed

**Table 4** Correlations between EASE total and clinical characteristics at follow-up \( (n = 32) \)

| Measures at f-u \( \rightarrow \) | SOPS pos | SOPS neg | SOPS disorg | SOPS gen | GAF-F |
|-------------------------------|---------|---------|-------------|----------|-------|
| EASE total at f-u              | 0.75*   | 0.76*   | 0.75*       | 0.64*    | -0.79* |

\(*p < 0.01\) (Bonferroni-adjusted), Spearman’s rho, two-tailed
was one outlier with a very strong increase in EASE total (see Fig. 1). The significant decline in EASE total scores from baseline to follow-up was found in females ($z = -2.94, p = 0.003$), but not in males ($z = -1.81, p = 0.07$). Males scored nominally higher on EASE total at follow-up ($Md = 12, n = 21$) than females ($Md = 4, n = 11$), but this difference was not significant ($U = 163.5, p = 0.06$).

Breaking the total sample down into three groups, seven subjects (21.9%) had an ≥ 1 point increase in EASE total from baseline ($Md = 21$) to follow-up ($Md = 27$), twelve subjects (37.5%) had a 0–3 points decline (baseline: $Md = 6$, follow-up: $Md = 4.5$), and thirteen subjects (40.6%) had a > 3 points decline (baseline: $Md = 16$, follow-up: $Md = 8$). The mean changes in EASE total scores for the three groups are illustrated in Fig. 2. Patients diagnosed with SSDs at follow-up ($n = 12$) did not have a significant decline in EASE total (baseline: $Md = 18.5$, follow-up: $Md = 16.5$), $z = -0.45, p = 0.96$. However, SSD subjects were found in all three groups: five increased, four declined 0–3 points, and three declined > 3 points.

Analyses revealed a statistically significant difference in baseline EASE levels between the three groups, $\chi^2 (2, n = 32) = 14.06, p = 0.001$. Post hoc comparison tests (Mann Whitney U) revealed that the median EASE total score for the ‘EASE 0–3 points decline group’ ($Md = 6$) was significantly lower than the median score in both the ‘EASE increase group’ ($Md = 21, p = 0.007$) and the ‘EASE > 3 points decline group’ ($Md = 16, p = 0.003$). Further analyses showed no other significant differences in baseline characteristics between the three groups.

Analyses of differences between the three trajectory groups revealed significant differences in SOPS positive change ($\chi^2 (2, n = 32) = 11.25, p = 0.004$) and in GAF-F change ($\chi^2 (2, n = 32) = 9.11, p = 0.01$), but not in the other three SOPS change variables. Mean change scores for the three groups are illustrated in Table 5. As can be

Table 5: Changes in SOPS symptoms and GAF-F in three EASE change groups

| EASE change | SOPS positive change $M (SD)$ | SOPS negative change $M (SD)$ | SOPS disorg change $M (SD)$ | SOPS general change $M (SD)$ | GAF-F change $M (SD)$ |
|-------------|-------------------------------|-------------------------------|-----------------------------|-----------------------------|----------------------|
| EASE increase (≥ 1 pt) | 2.00 (5.69) | −0.86 (6.28) | 0.71 (4.46) | −1.29 (4.31) | −8.43 (8.60) |
| EASE 0–3 pt decline | −4.08 (4.91) | −1.33 (4.21) | −1.92 (2.88) | −2.08 (4.38) | 7.83 (10.04) |
| EASE > 3 pt decline | −6.77 (3.30) | −4.62 (3.62) | −3.00 (2.16) | −3.85 (3.74) | 5.77 (10.58) |

* Exact $p$ value $^a$ | 0.004* | 0.085 | 0.052 | 0.273 | 0.011* |

$^a$Kruskal Wallis test, $^* p < .05$
seen, there was a nominal increase in positive symptoms and a decreased functioning in the EASE increase group. This contrasted significantly with the decrease in positive symptoms and the increased functioning at follow-up in the two other groups.

**Discussion**

**Baseline characteristics and EASE total at follow-up**

The strong, positive correlation between baseline negative symptoms and BSD levels at one-year follow-up was in line with the strong association between negative symptoms and BSD levels at baseline found in a previous study of this sample (also including the six drop-outs) [77]. This may imply that a higher severity of negative symptoms in CHR may be associated with a higher probability of sustained or recurring high BSD levels as future outcomes. However, this of course does not necessarily mean that negative symptoms cause BSD, or vice versa. Phenomenologically oriented theories suggest that negative symptoms (along with other clinical manifestations) are meaningful, intimately interconnected aspects of an underlying psychopathological "Gestalt", characterized by disturbances in the structure of subjectivity, i.e. BSD [42, 64, 67]. Basic symptoms may also constitute such aspects [43–45], thus possibly explaining that subjects meeting COGDIS criteria at baseline had higher levels of BSD at follow-up than the other participants (also when removing EASE items from the analyses clearly overlapping with the COGDIS items). The significantly higher BSD levels at follow-up, as well as at baseline [77], in subjects assessed with SPD at baseline, were in line with other studies demonstrating that SPD and ICD-10 schizotypal disorder are associated with BSD levels markedly higher than in conditions outside of the schizophrenia spectrum [22, 40, 55, 57].

The results indicated better outcomes in females than males with respect to future BSD levels (a significant decline). Studies have found more severe negative symptoms and poorer social functioning in CHR males [2, 59], which are characteristics associated with poorer clinical and functional prognosis in several studies, e.g. [4, 10, 25, 68]. Considering that BSD levels and negative symptoms were strongly associated in this study, the better outcome in females seems not surprising. However, the severity of negative symptoms was only nominally higher in males at both time points. Gender differences are underexplored as a research topic in CHR studies, and have been found to be rather small [28]. Hence, the differences found in the current and other studies should be investigated in larger samples.

We can only speculate about the lack of a significant effect of medication and other aspects of treatment on EASE total and other clinical variables at baseline and follow-up. The small sample size may have diminished the probability of finding such effects. The effect of medication on BSD is another underexplored field, and for the majority of subjects prescribed antipsychotics, daily doses were considerably below what is considered having an antipsychotic effect.

**EASE total at follow-up vs. other characteristics at follow-up**

The strong associations at follow-up between high BSD levels, lower level of global functioning and higher severity of symptoms on all SOPS subscales, point to a consolidation of a psychopathological Gestalt with BSD as a core feature, accruing as time has passed. The more severe clinical pattern found in SSD subjects fits well with the BSD/ipseity disturbance model [36, 42, 48, 65, 67]. An alternative hypothesis is that BSD may be a marker of elevated (severe) levels of a “general psychopathology” (p) factor crossing symptomatic domains and diagnostic boundaries [11], increasing the risk of the psychopathological expressions typically found in the SSDs.

Our results contrast to some extent with the findings in a 5-year follow-up study, investigating associations between BSD levels, positive and negative symptoms, and functioning in schizophrenia spectrum patients [39]. In this study, only positive symptoms at follow-up correlated with BSD levels at follow-up. In addition, significant correlations were found between baseline BSD and global symptom levels at baseline and follow-up [39]. It is likely that the difference between these two studies is due to stronger diagnostic homogeneity and higher severity of the sample in the 5-year follow-up study, in comparison with the heterogeneous CHR sample in the current study.

A possible explanation for the weaker correlations between baseline SOPS subscale and GAF-F variables and BSD levels at follow-up, compared to the correlations only including follow-up equivalents of these variables, could be that the symptoms measured by SOPS and GAF are affected by many other factors than BSD in early CHR conditions. Attenuated psychotic symptoms are not uncommon in youth with mental health concerns and functional decline [12, 76, 79], and not even in the general population [23, 26]. These attenuated symptoms may constitute quite non-specific reactions to stressful conditions, rather than be driven by BSD [32]. Hence, they may also be of a transient or fluctuating nature in many CHR subjects. In addition, weaker correlations at baseline between BSD and positive symptoms may reflect a more restricted range of positive symptoms at baseline, due to the inclusion criteria. Dysfunction in CHR may also vary and improve as time unfolds [68], though it may also have a non-remitting or even deteriorating course in these conditions [38, 68].
Changes in EASE total and associations with other characteristics

Median BSD levels decreased in the total sample, but individual BSD trajectories varied considerably. This might indicate that BSD is not unconditionally trait-like and stable in CHR conditions. According to a recent suggested revision of the self-disorder model [7, 62, 66], some BSD phenomena may have a ‘secondary’, reactive, state-like quality, due to the interaction between adverse environmental circumstances and individual vulnerabilities. These are assumed to occur in SSDs, but also in dissociative and anxiety conditions [27, 63, 78]. Possibly, they are also frequent in CHR conditions. Other BSD phenomena may be more ‘primary’, ‘automatic’, stable features, possibly reflecting early neurodevelopmental disturbances [53]. These may be more specific to SSDs and prodromal schizophrenia. Individual differences in the predominance of primary versus secondary BSD phenomena could possibly manifest in different BSD trajectories.

As a group, subjects with SSD diagnoses at follow-up did not show a significant decline in BSD levels, but some had and increase while others had a small or a marked decline. The EASE increase group (5 of 7 with SSDs) was characterized by a more severe clinical pattern, including higher baseline levels of BSD, and symptomatic and functional non-remission at follow-up. Svendsen et al. [75] also found increasing, stable and decreasing BSD levels in patients with schizophrenia. As suggested by these authors, BSD levels may be more influenced by individual characteristics, including response to treatment, than previously thought [8, 46]. In the current study, subjects with a 0–3 points decline in EASE total had significantly lower BSD levels at baseline than the other participants. Given the low levels at baseline, which implies a good prognostic sign, it is not surprising that these levels were still low and stable at follow-up.

The revised BSD model remains to be properly tested. This would require prospective studies in larger samples than the current study, investigating the presence and stability of BSD in patients from different diagnostic groups, and addressing both intra-individual patterns and inter-individual differences. It should also be noted that changes in EASE scores may not necessarily reflect more or less anomalous self-experiences, but may also be due to variations in the “availability” (mental awareness) of experiences for the person, and the ability to communicate them [34, 49].

Limitations

The firmness of the conclusions is restricted due to the small sample size, which also included the ‘non-progressive symptoms group’. We partly controlled for this limitation by doing all analyses with and without the ‘non-progressive’ subjects, and this did not affect the results. Analyses comparing the small subgroups in the sample may have increased the risk of type I and type II errors. Including a larger control group of help-seeking non-CHR subjects with no positive symptom inclusion criterion, would have been appropriate to avoid the problem of the restricted range of positive symptoms at baseline. This would also have increased the possibility of doing comparative analyses, and thus the generalizability of the results. The ad hoc approach to the categorization of BSD trajectories in three groups is another limitation. Finally, the rater doing the follow-up assessments should have been blind to the baseline findings. On the other hand, this is to our knowledge the first CHR study investigating with the full EASE scale at two time points. In light of the small sample, findings are primarily of interest to generate hypotheses well worth investigating in larger samples.

Conclusions

This study found that CHR subjects characterized by more severe negative symptoms, cognitive disturbances and higher BSD levels at baseline were particularly vulnerable for a consolidation of a comprehensive psychopathological Gestalt as time passed, with BSD as a core feature. In line with the BSD model, this consolidation was more common in subjects with SSDs (9 of 12 with SPD) at follow-up. The general decrease in BSD levels, together with the individual variations in BSD trajectories, indicated that BSD phenomena in CHR conditions may vary with respect to having a state-like or a trait-like character, in line with the suggested revision of the self-disorder model [62]. Increasing BSD levels may constitute a marker of a non-remitting or even progressively worsening symptomatic and functional course. Taken together, the results demonstrated that longitudinal investigations of BSD are helpful in identifying CHR subjects at particularly high risk for adverse symptomatic and functional outcomes, even in non-converting to psychosis cases. If replicated in prospective CHR studies with larger samples, these findings may contribute considerably to the clinical identification of such particularly vulnerable CHR subjects.

Supplementary Information. The online version contains supplementary material available at https://doi.org/10.1007/s00406-021-01349-6.
Funding Open access funding provided by University of Oslo (incl Oslo University Hospital). This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Declarations

Conflict of interests The authors declare that they have no conflicts of interest concerning this article.

Ethical approval All participants gave written informed consent. For those below 18 years, parents consented as well. The study was approved by the Regional Committee for Medical Research Ethics (REC South-East) in Norway (permission number 2011/1070 D), and was conducted in accordance with the 1964 Declaration of Helsinki.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. American Psychiatric A (2013) Diagnostic and statistical manual of mental disorders, fifth edition (dsm-5®). American Psychiatric Publishing, Washington, D.C.
2. Barajas A, Ochoa S, Obiols JE, Lalucat-Jo L (2015) Gender differences in individuals at high-risk of psychosis: A comprehensive literature review. TheScientificWorldJournal 2015:430735
3. Beck K, Andreou C, Studerus E, Heitz U, Ittig S, Leanza L, Riecher-Rossler A (2019) Clinical and functional long-term outcome of patients at clinical high risk (chr) for psychosis without transition to psychosis: A systematic review. Schizophr Res
4. Beck K, Andreou C, Egloff L, Leanza L, Simon AE, Borgwardt S, Riecher-Rossler A (2019) Clinical and functional ultra-long-term outcome of patients with a clinical high risk (chr) for psychosis. Eur Psychiatry 62:30–37
5. Bernstein DP, Ahluvalia T, Pagge D, Handelsman L (1997) Validity of the childhood trauma questionnaire in an adolescent psychiatric population. J Am Acad Child Adolesc Psychiatry 36:340–348
6. Bernstein DP, Stein JA, Newcomb MD, Walker E, Pagge D, Ahluvalia T, Stokes J, Handelsman L, Medrano M, Desmond D, Zule W (2003) Development and validation of a brief screening version of the childhood trauma questionnaire. Child Abuse Negl 27:169–190
7. Borda JP, Sass LA (2015) Phenomenology and neurobiology of self disorder in schizophrenia: Primary factors. Schizophr Res 169:464–473
8. Bovet P, Parnas J (1993) Schizophrenic delusions: A phenomenological approach Schizophr Bull 19:579–597
9. Cannon-Spoo HE, Potkin SG, Wyatt RJ (1982) Measurement of premorbid adjustment in chronic schizophrenia. Schizophr Bull 8:470–484
10. Carrion RE, Demmim D, Auther AM, McLaughlin D, Olsen R, Lenzcz T, Correll CU, Cornblatt BA (2016) Duration of attenuated positive and negative symptoms in individuals at clinical high risk: Associations with risk of conversion to psychosis and functional outcome. J Psychiatr Res 81:95–101
11. Caspi A, Moffitt TE (2018) All for one and one for all: Mental disorders in one dimension. Am J Psychiatry 175:831–844
12. Clarke S, Hanna D, Davidson S, Shannon C, Mulholland C (2020) The association between sleep quality and attenuated psychotic symptoms. Early Interv Psychiatry
13. Comparrelli A, Corigliano V, De Carolis A, Pucci D, Angelone M, Di Pietro S, Kotzialis GD, Terzario L, Manni L, Trisolini A, Girardi P (2016) Anomalous self-experiences and their relationship with symptoms, neuro-cognition, and functioning in at-risk adolescents and young adults. Compr Psychiatry 65:44–49
14. Davidsen KA (2009) Anomalous self-experience in adolescents at risk of psychosis. Clin Concept Elucidation Psychopathol 42:361–369
15. Ettinger U, Meyhofer I, Steffens M, Wagner M, Koutsouleris N (2014) Genetics, cognition, and neurobiology of schizotypal personality: A review of the overlap with schizophrenia. Front Psychiat 5:18
16. First MB (1997) Structured clinical interview for dsm-iv axis i disorders (scid-i): Clinician version : User’s guide for the structured clinical interview for dsm-iv axis i disorders. American Psychiatr Press, Washington, D.C.
17. Fuchs T (2015) From self-disorders to ego disorders. Psychopathology 48:324–331
18. Fusar-Poli P, Bonoldi I, Yung AR, Borgwardt S, Kempton MJ, Valmaggia L, Barale F, Caverzasi E, McGuire P (2012) Predicting psychosis: Meta-analysis of transition outcomes in individuals at high clinical risk. Arch Gen Psychiatry 69:220
19. Fusar-Poli P, Borgwardt S, Bechdolf A, Addington J, Riecher-Rossler A, Schultz-Lutter F, Keshavan M, Wood S, Ruhrmann S, Seidman LJ, Valmaggia L, Cannon T, Velthorst E, De Haan L, Cornblatt B, Bonoldi I, Birchwood M, McGlashan T, Carpenter W, McGorry P, Klosterkotter J, McGuire P, Yung A (2013) The psychosis high-risk state: A comprehensive state-of-the-art review. JAMA Psychiat 70:107–120
20. Fusar-Poli P, Cappuccitti M, Rutigliano G, Lee TY, Beverly Q, Bonoldi I, Lelli J, Kaar SJ, Gago E, Rocchetti M, Patel R, Bhavsar V, Tognin S, Badger S, Calem M, Lim K, Kwon JS, Perez J, McGuire P (2016) Towards a standard psychometric diagnostic interview for subjects at ultra high risk of psychosis: Caarms versus sips. Psychiatry J 2016:7146341
21. Fusar-Poli P, Salazar de Pablo G, Correll CU, Meyer-Lindenberg A, Millan MJ, Borgwardt S, Galderisi S, Bechdolf A, Pfennig A, Kessing LV, van Amelsvoort T, Nieman DH, Domschke K, Krebs MO, Koutsouleris N, McGuire P, Do KQ, Arango C (2020) Prevention of psychosis: Advances in detection, prognosis, and intervention. JAMA psychiatry
22. Hanestad P, Parnas J (2005) Clinical characteristics of first-admitted patients with icd-10 schizotypal disorder. Br Psychiatr Suppl 187:s49–s54
23. Kelleher I, Connor D, Clarke MC, Devlin N, Harley M, Cannon M (2012) Prevalence of psychotic symptoms in childhood and adolescence: A systematic review and meta-analysis of population-based studies. Psychiat Med 42:1857–1863
24. Koren D, Tzivoni Y, Schalit L, Adres M, Reznik N, Apter A, Parnas J (2019) Basic self-disorders in adolescence predict schizophrenia spectrum disorders in young adulthood: A 7-year follow-up study among non-psychotic help-seeking adolescents. Schizophr Res
25. Koutsouleris N, Kambeitz-Illankovic L, Ruhrmann S, Rosen M, Rief A, Dwyer DB, Paolini M, Chisholm K, Kambeitz J, Haid T, Schmidt A, Gilliam J, Schulze-Lutter F, Falkai P, Reiser M, Riecher-Rössler A, Uphoegrove R, Hietala J, Salokangas RKR, Pantelis C, Meisenzahl E, Wood SJ, Beque D, Brambilla P, Borgwardt S (2018) Prediction models of functional outcomes for individuals in the clinical high-risk state for psychosis or with recent-onset depression: A multimodal, multisite machine learning analysis. JAMA Psychiatry 75:1156–1172

26. Linscott R, van Os J (2013) An updated and conservative systematic review and meta-analysis of epidemiological evidence on psychotic experiences in children and adults: On the pathway from proneness to persistence to dimensional expression across mental disorders. In: Cambridge University Press, Cambridge, p 1133–1149

27. Madeira L, Carenmates S, Costa C, Linhares L, Stanghellini G, Figueira ML, Sass L (2017) Basic self-disturbances beyond schizophrenia: Discrepancies and affinities in panic disorder - an empirical clinical study. Psychopathology 50:157–168

28. Menghini-Müller S, Stederus E, Ittig S, Heitz U, Egloff L, Andreou C, Valmaggia LR, Kempton MJ, van der Gaag M, de Haan L, Nelson B, Barrantes-Vidal N, Nordenfelt M, Ruhrmann S, Sachs G, Rutten BP, Os Jv, Riecher-Rössler A, McGuire P, Valmaggia LR, Kempton MJ, Calem M, Tognin S, Modinos G, de Haan L, van der Gaag M, Velthorst E, Kraa TC, van Dam DS, Burger N, Nelson B, McGorry P, Amminger GP, Pantelis C, Politis A, Goodall J, Riecher-Rössler A, Borgwardt S, Rapp C, Ittig S, Studerus E, Smieskova R, Bressan R, Gadelha A, Brietzke E, Asevedo G, Asevedo E, Zugman A, Barrantes-Vidal N, Dominguez-Martínez T, Racioppi A, Cristóbal-Narváez P, Kwapiel TR, Monsonet M, Kazes M, Daban C, Bourgin J, Gay O, Mam-Lam-Fook C, Krebs MO, Nordholm D, Randers L, Krakauer K, Glenthøj L, Glenthøj B, Nordenfelt M, Ruhrmann S, Gehbarg D, Arnhold J, Klosterkötter J, Sachs G, Lasser J, Winklbaeur B, Delespaul PA, Rutten BP, van Os J (2019) Gender differences of patients at-risk for psychosis regarding symptomatology, drug use, comorbidity and functioning - results from the eu-goi study. Eur Psychiatry 59:52–59

29. Miller TJ, McGlashan TH, Rosen JL, Cadenhead K, Cannon T, Ventura J, McFarlane W, Perkins DO, Pearlson GD, Woods SW (2003) Prodromal assessment with the structured interview for prodromal syndromes and the scale of prodromal symptoms: Predictive validity, interrater reliability, and training to reliability. Schizophr Bull 29:703–715

30. Miller TJ, McGlashan TH, Rosen JL, Somjee L, Markovich PJ, Stein K, Woods SW (2002) Prospective diagnosis of the initial prodrome for schizophrenia based on the structured interview for prodromal syndromes: Preliminary evidence of interrater reliability and predictive validity. Am J Psychiatry 159:863–865

31. Miller TJ, McGlashan TH, Woods SW, Stein K, Driesen N, Corcoran CM, Hoffman R, Davidson L (1999) Symptom assessment in schizophrenic prodromal states. PsychiatrQ 70:273–287

32. Millman ZB, Pitts SC, Thompson E, Kline ER, Demro C, Weinberg M, Parnas J, Raballo A, Handest P, Jansson L, Saebye D, Bressan R, Gadelha A, Brietzke E, Asevedo G, Asevedo E, Zugman A, Barrantes-Vidal N, Dominguez-Martínez T, Racioppi A, Cristóbal-Narváez P, Kwapiel TR, Monsonet M, Kazes M, Daban C, Bourgin J, Gay O, Mam-Lam-Fook C, Krebs MO, Nordholm D, Randers L, Krakauer K, Glenthøj L, Glenthøj B, Nordenfelt M, Ruhrmann S, Gehbarg D, Arnhold J, Klosterkötter J, Sachs G, Lasser J, Winklbaeur B, Delespaul PA, Rutten BP, van Os J (2019) Gender differences of patients at-risk for psychosis regarding symptomatology, drug use, comorbidity and functioning - results from the eu-goi study. Eur Psychiatry 59:52–59

33. Moller P, Haug E, Raballo A, Melle I (2011) Examination of anomalous self-experience in first-episode psychosis: Interrater reliability. Psychopathology 44:386–390

34. Moller P, Husby R (2000) The initial prodrome in schizophrenia: Searching for naturalistic core dimensions of experience and behavior. Schizophr Bull 26:217–232

35. Nelson B, Parnas J, Sass LA (2014) Disturbance of minimal self (ipseity) in schizophrenia: Clarification and current status. Schizophr Bull 40:479–482

36. Nelson B, Raballo A (2015) Basic self-disturbance in the schizophrenia spectrum: Taking stock and moving forward. Psychopathology 48:301–309

37. Nelson B, Thompson A, Yung AR (2012) Basic self-disturbance predicts psychosis onset in the ultra high risk for psychosis “prodromal” population. Schizophr Bull 38:1277–1287

38. Niendam TA, Bearden CE, Zinberg J, Johnson JK, O’Brien M, Cannon TD (2007) The course of neurocognition and social functioning in individuals at ultra high risk for psychosis. Schizophr Bull 33:772–781

39. Nordgaard J, Nilsson LS, Saebøe D, Parnas J (2017) Self-disorders in schizophrenia-spectrum disorders: A 5-year follow-up study. Eur Arch Psychiatry Clin Neurosci

40. Nordgaard J, Parnas J (2014) Self-disorders and the schizophrenia spectrum: A study of 100 first hospital admissions. Schizophr Bull 40:1300–1307

41. Norgaard J, Parnas J (2012) A semi structured, phenomenologically oriented psychiatric interview: Descriptive congruence in assessing anomalous subjective experience and mental status. Clin Neuropsychiatry 9:123

42. Parnas J (2011) A disappearing heritage: The clinical core of schizophrenia. Schizophr Bull 37:1121–1130

43. Parnas J, Handest P (2003) Phenomenology of anomalous self-experience in early schizophrenia. Compr Psychiatry 44:121–134

44. Parnas J, Handest P, Jansson L, Saebøe D (2005) Anomalous subjective experience among first-admitted schizophrenia spectrum patients: Empirical investigation. Psychopathology 38:259–267

45. Parnas J, Handest P, Saebøe D, Jansson L (2003) Anomalies of subjective experience in schizophrenia and psychotic bipolar illness. Acta Psychiatr Scand 108:126–133

46. Parnas J, Henriksen MG (2014) Disordered self in the schizophrenia spectrum: A clinical and research perspective. Harv Rev Psychiatry 22:251–265

47. Parnas J, Jansson L, Sass LA, Handest P (1998) Self-experience in the prodromal phases of schizophrenia: A pilot study of first admissions. Neurol Psychiatry Brain Res 6:97–106

48. Parnas J, Jansson LB (2015) Self-disorders: Clinical and conceptual implications for the diagnostic concept of schizophrenia. Psychopathology 48:332–338

49. Parnas J, Moller P, Kircher T, Thalbitzer J, Jansson L, Handest P, Zahavi D (2005) Ease: Examination of anomalous self-experience. Psychopathology 38:236–258

50. Parnas J, Raballo A, Handest P, Jansson L, Vollmer-Larsen A, Saebøe D (2011) Self-experience in the early phases of schizophrenia: 5-year follow-up of the Copenhagen prodromal study. World Psychiatry 10:200–204

51. Pedersen G, Hagtvet KA, Karterud S (2007) Generalizability studies of the global assessment of functioning-split version. Compr Psychiatry 48:88–94

52. Polari A, Lavoie S, Yuen HP, Amminger P, Berger G, Chen E, de Haan L, Hartmann J, Markulev C, Melville F, Nieman D, Nordenfelt M, Riecher-Rossler A, Smesny S, Stratford J, Verma S, Yung A, McGorry P, Nelson B (2018) Clinical trajectories in the ultra-high risk for psychosis population. Schizophr Res 197:550–556

53. Postmes T, Sno HN, Goedhart S, van der Stel J, Heering HD, de Haan L (2014) Schizophrenia as a self-disorder due to perceptual incoherence. Schizophr Res 152:41–50

54. Raballo A, Pappagallo E, Deli’ Erba A, Lo Cascio N, Patane M, Gebhardt E, Boldrini T, Terzariol L, Angelone M, Trisolini A, Girardi P, Fiori Nastro P (2016) Self-disorders and clinical high risk for psychosis: An empirical study in help-seeking youth attending community mental health facilities. Schizophr Bull 42:926–932
55. Raballo A, Parnas J (2012) Examination of anomalous self-experience: Initial study of the structure of self-disorders in schizophrenia spectrum. J Nerv Ment Dis 200:577–583
56. Raballo A, Parnas J (2010) The silent side of the spectrum: Schizotypy and the schizotypic self. Schizophren Bull
57. Raballo A, Poletti M, Preti A, Parnas J (2021) The self in the spectrum: A meta-analysis of the evidence linking basic self-disorders and schizophrenia. Schizophren Bull
58. Raballo A, Saebø D, Parnas J (2009) Looking at the schizophrenic spectrum through the prism of self-disorders: An empirical study. Schizophren Bull
59. Rietveld L, Lambert M, Karow A, Zink M, Müller H, Heinz A, de Millas W, Janssen B, Guebel W, Schneider F, Naber D, Juckel G, Krüger-Özgürdal S, Wobrock T, Wagner M, Maier W, Klosterkötter J, Bechdolf A (2017) Clinical high risk for psychosis: Gender differences in symptoms and social functioning. Early Interv Psychiatry 11:306–313
60. Ruhrmann S, Schultz-Lutter F, Salokangas RK, Heinimaa M, Linszen D, Dingemans P, Birchwood M, Patterson P, Juckel G, Heinz A, Morrison A, Lewis S, von Reventlow HG, Klosterkötter J (2010) Prediction of psychosis in adolescents and young adults at high risk: Results from the prospective European prediction of psychosis study. Arch Gen Psychiatry 67:241–251
61. Salazar de Pablo G, Catalan A, Fusar-Poli P (2019) Clinical validity of DSM-5 attenuated psychosis syndrome: Advances in diagnosis, prognosis, and treatment. JAMA Psychiatry
62. Sass L, Borda JP, Madeira L, Pienkos E, Nelson B (2018) Varieties of self disorder: A bio-pheno-social model of schizophrenia. Schizophren Bull 44:720–727
63. Sass L, Pienkos E, Nelson B, Medford N (2013) Anomalous self-experience in depersonalization and schizophrenia: A comparative investigation. Conscious Cogn 22:430–441
64. Sass LA (2003) "Negative symptoms", schizophrenia, and the self. [references]. International Journal of Psychology & Psychological Therapy:153–180
65. Sass LA (2014) Self-disturbance and schizophrenia: Structure, specificity, pathogenesis (current issues, new directions). Schizophren Res 162:79–85
66. Sass LA, Borda JP (2015) Phenomenology and neurobiology of self disorder in schizophrenia: Secondary factors. Schizophren Res 169:474–482
67. Sass LA, Parnas J (2003) Schizophrenia, consciousness, and the self. Schizophren Bull 29:427–444
68. Schlosser DA, Jacobson S, Chen Q, Sugar CA, Niendam TA, Li G, Bearden CE, Cannon TD (2012) Recovery from an at-risk state: Clinical and functional outcomes of putatively prodromal youth who do not develop psychosis. Schizophren Res 38:1225–1233
69. Schmidt SJ, Schultz-Lutter F, Schimmelmann BG, Maric NP, Salokangas RK, Riecher-Rossler A, van der Gaag M, Meneghelli A, Nordentoft M, Marshall M, Morrison A, Raballo A, Klosterkottter J, Ruhrmann S (2015) Epa guidance on the early intervention in clinical high risk states of psychoses. Eur Psychiatry 30:388–404
70. Schultz-Lutter F, Addington J, Ruhrmann S, Klosterkötter J (2007) Schizophrenia proneness instrument: Adult version (spi-a). Giovanni Fioriti Editore, Roma
71. Schultz-Lutter F, Klosterkötter J, Picker H, Steinmeyer E-M, Ruhrmann S (2007) Predicting first-episode psychosis by basic symptom criteria. Clin Neuropsychiatry 4:11–22
72. Schultz-Lutter F, Michel C, Schmidt SJ, Schimmelmann BG, Maric NP, Salokangas RK, Riecher-Rossler A, van der Gaag M, Nordentoft M, Raballo A, Meneghelli A, Marshall M, Morrison A, Ruhrmann S, Klosterkötter J (2015) Epa guidance on the early detection of clinical high risk states of psychoses. Eur Psychiatry 30:405–416
73. Schultz-Lutter F, Nenadic I, Grant P (2019) Psychosis and schizophrenia-spectrum personality disorders require early detection on different symptom dimensions. Front Psych 10:4746
74. Stanghellini G (2000) Vulnerability to schizophrenia and lack of common sense. Schizophren Bull 26:775–787
75. Svendsen IH, Oie MG, Moller P, Nelson B, Melle I, Haug E (2018) Stability in basic self-disturbances and diagnosis in a first treated psychosis: A seven year follow-up study. Schizophren Res
76. Thompson E, Kline E, Ellman LM, Mittal V, Reeves GM, Schiffman J (2015) Emotional and behavioral symptomatology reported by help-seeking youth at clinical high-risk for psychosis. Schizophren Res 162:79–85
77. Vaernes TG, Rossberg JI, Moller P (2019) Anomalous self-experiences are strongly associated with negative symptoms in a clinical high-risk for psychosis sample. Compr Psychiatry 93:65–72
78. Vaernes TG, Rossberg JI, Moller P (2018) Anomalous self-experiences: Markers of schizophrenia vulnerability or symptoms of depersonalization disorder? A phenomenological investigation of two cases. Psychopathology:1–12
79. van Os J, Gulokusz S (2017) A critique of the “ultra-high risk” and “transition” paradigm. World Psychiatry 16:200–206
80. Viersen TG, Rossberg JI, Moller P (2021) Basic self-disturbance in subjects at clinical high risk for psychosis: Relationship with clinical and functional outcomes at one year follow-up. Psychiatry Res 300:113942
81. Woods SW, Walsh BC, Addington J, Cadenhead KS, Cannon TD, Cornblatt BA, Heinssen R, Perkins DO, Seidman LJ, Tarbox SI, Tsuang MT, Walker EF, McGlashan TH (2014) Current status specifiers for patients at clinical high risk for psychosis. Schizophren Res 158:69–75
82. Woods SW, Walsh BC, Powers AR, McGlashan TH (2019) Reliability, validity, epidemiology, and cultural variation of the structured interview for psychosis-risk syndromes (sips) and the scale of psychosis-risk symptoms (sops). In: Cham: Springer International Publishing, Cham, p 85–113